Foghorn Therapeutics Stock Extends Decline After Eli Lilly Partnership Ends

Foghorn Therapeutics (NASDAQ: FHTX) saw its stock plummet on Tuesday, falling 31.2% to $2.01 in afternoon trading. The sharp decline extends a brutal sell-off following the termination of its strategic collaboration with Eli Lilly and a subsequent series of downgrades from Wall Street analysts.

Partnership Terminated Over Efficacy Concerns

The sell-off began after Foghorn and Eli Lilly jointly announced they would not advance their drug candidate, FHD-909, into the next phase of clinical trials. A review of the Phase 1 dose escalation study showed the drug's underlying biology failed to translate into the required level of clinical efficacy.

As a result of the disappointing data, the two companies have ended all collaboration activities. This includes the discontinuation of a separate, selective SMARCA2 degrader program, effectively dissolving the entire partnership that had been a cornerstone of Foghorn's development strategy.

Analysts Downgrade Stock, Slash Price Targets

The continued downward pressure on the stock was fueled by a coordinated reassessment from investment firms. Analysts' actions included:

Ad

• Wedbush: Downgraded the stock to Neutral from Outperform and cut its price target to $2 from $10, noting the Lilly partnership was a central part of its previous bullish thesis.
• BTIG: Downgraded the stock to Neutral from Buy.
• TD Cowen: Downgraded the stock to Hold from Buy.
• Other Price Target Reductions: H.C. Wainwright lowered its target to $5 from $13, while both Guggenheim and Stifel cut their targets to $5 from $12.

Restructuring and Future Outlook

In response to the pipeline setback, Foghorn announced a significant organizational restructuring that includes a workforce reduction of approximately 40%. The company stated this measure is expected to extend its cash runway into the second half of 2029.

However, with the termination of the Lilly-partnered programs, Foghorn's entire development pipeline is now in the preclinical stage. This raises significant questions for investors regarding the company's near-term catalysts and its ability to secure new partnerships or capital to advance its remaining programs, such as its EP300 degrader, toward clinical trials.